Ars Pharmaceuticals had a nice pop today and is currently up 6.54% -- which is pretty good. Investors have a more positive outlook for the company and future revenue.
Currently SPRY isn't at a clear support/resistance line that seems tradable. Ars Pharmaceuticals hasn't established a very strong momentum in either direction over the last 3 months. We'll see if a stronger consensus among market participants emerges. SPRY might find some support at the 2.79 level, buyers might push the price back up from here. But it's not very clear what will happen.